Multiple System Atrophy
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
Subtype terms (3)
More specific conditions that are subtypes of Multiple System Atrophy in the MeSH hierarchy.
- Olivopontocerebellar Atrophies
- Shy-Drager Syndrome
9 drugs (7 approved, 2 experimental)
- Striatonigral Degeneration
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (6)
Phase 2 trials (25)
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (24)
- PPD
- Chelsea Therapeutics
- Aventis
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of London
- German Center for Neurodegenerative Diseases (DZNE)
- German Parkinson Study Group (GPS)
- New York University
- University of Michigan
- Mayo Clinic
- University of Ulm
- Vanderbilt University
- University of Toulouse
- National Taiwan University
- Ludwig Maximilians University
- University of Paris
- Biohaven Pharmaceuticals Inc.
- General Electric
- Deutsche Parkinson Vereinigung
- Deutsche Stiftung Neurologie
- ParkinsonFonds Deutschland gGmbH
- Rare Disease Research Network Autonomic Consortium
- Competence Network on Parkinson's Disease
- European MSA-Study Group
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (12)
- Biogen
- Corestem, Inc.
- Affiris AG
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Bordeaux
- University of Queensland
- Fundació per a la Recerca Biomedica
- University of Barcelona
- National Center for Advancing Translational Science (NCATS)
- Forschungszentrum Jülich
Organization Involved with Other Experimental Indications (5)